RAS LSS Consulting

Struggling to bring your innovation to market? The odds are steep - only 1 in 10,000 medicines make it from the lab to the market. The path is complex, with hurdles in #RandD, #RegulatoryApprovals, and #MarketDifferentiation.   At #RASLSSConsulting, we don't increase the odds of success...you do. We just operate behind the scenes, delivering #Insights that help you take bold #Decisions with confidence.   🔍 Watch our video to learn more, or reach out to see how we can help. #RASLSSConsulting - guiding you all the way, from lab to market. #RASLifeScienceSolutions #PharmaConsulting #LifeSciences #Innovation #Strategy #GetInTouch #Sevices #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #ManagementConsulting #MatchMaking #RandSupportServices #PortfolioOptimization #ConferenceCoverage #MarketEntryStrategy #PartnerIdentification

✨ Wishing everyone celebrating a joyous and blessed Eid al-Fitr!! ✨ May this occasion bring peace, happiness, and prosperity to you and your loved ones!! 🎉 #EidMubarak #EidAlFitr #RASLSSConsulting

A significant partnership is taking shape in the biopharmaceutical industry, as The United Laboratories International LLC Holdings Limited (#TUL) and Novo Nordisk have announced an exclusive license agreement for UBT251. This novel compound is a triple receptor agonist, targeting the GLP-1, GIP, and glucagon receptors, and holds promising potential in the treatment of #obesity, #type2diabetes, and other related diseases. Under the terms of this agreement, Novo Nordisk will gain exclusive worldwide rights, excluding the #Chinesemainland, Hong Kong, Macau, and Taiwan, to develop, manufacture, and commercialize UBT251. This strategic move leverages Novo Nordisk's extensive global reach and expertise in bringing innovative therapies to patients worldwide. The collaboration is also a significant development for United Biotechnology, a subsidiary of #TUL, which will receive a substantial upfront payment of $200 million USD and the potential for up to $1.8 billion USD in milestone payments from Novo Nordisk. Additionally, United Biotechnology will benefit from tiered royalties on net sales outside of the Greater China region, reflecting the value of this promising early-stage asset. Early clinical data for UBT251 has shown encouraging results. A phase 1b trial demonstrated that participants in the highest dose group experienced an average weight loss of 15.1%. The safety profile of UBT251 was consistent with incretin-based therapies. This collaboration between Novo Nordisk and #TUL represents a pivotal moment in the advancement of innovative treatments for chronic diseases. It highlights the power of #strategicpartnerships in accelerating the development and global reach of promising therapeutic candidates. Congratulations to both organizations on this exciting venture! 🎉 Detailed News: https://lnkd.in/dG_sptBZ Follow our page for more industry updates: https://lnkd.in/de5zNWmK Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv #NovoNordisk #TUL #TheUnitedLaboratories #Obesity #RASLSSConsulting #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification

AstraZeneca's Strategic Acquisition of EsoBiotec and the Future of #ENaBLTechnology in Treating Complex Diseases!🚀 This move is driven by the transformative potential of EsoBiotec's Engineered NanoBody Lentiviral (#ENaBL) platform, a technology poised to revolutionize how we approach complex diseases like #cancer and #immunemediateddisorders. The core innovation is the ability to deliver genetic instructions directly to specific immune cells, like T cells, within the body using targeted lentiviruses. This reprograms cells to target and destroy cancerous or autoreactive cells, offering a more efficient alternative to traditional cell therapies that require cell removal, genetic modification, and reinfusion. EsoBiotec's #ENaBLplatform streamlines this process, enabling cell therapies to be administered via a simple intravenous injection, thereby significantly reducing treatment time from weeks to mere minutes. Furthermore, it eliminates the need for immune cell depletion, a procedure often associated with significant side effects.   The implications of this acquisition extend beyond the simplification of treatment protocols. By making cell therapies more accessible and efficient, AstraZeneca aims to broaden the reach of these life-saving treatments to a #largerpatientpopulationworldwide. The $1 billion investment, comprising an initial $425 million payment and up to $575 million in contingent milestones, underscores AstraZeneca's commitment to realizing the full potential of #celltherapy. The acquisition not only strengthens AstraZeneca's existing cell therapy pipeline but also aligns with its broader vision of leading a revolution in #oncology and addressing the underlying #drivers of #immunemediateddiseases.   Detailed News: https://lnkd.in/diF_QWpZ Follow our page for more industry updates: https://lnkd.in/de5zNWmK Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv #EsoBiotec #AstraZeneca #CellTherapy #RASLSSConsulting #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification

Roche inks US$1.65bn #obesity deal with Zealand Pharma!🎉 Danish Zealand Pharma A/S and F. Hoffmann-LaRoche Ltd have entered into a licensing agreement to jointly develop and commercialize Zealand Pharma’s Phase II long-acting #amylinmimetic, #petrelintide, for #weightmanagement in #overweight and #obese individuals. This collaboration also includes the development and commercialization of drug combinations, such as #petrelintide/CT-388, which Roche acquired in 2023 through the purchase of Carmot Therapeutics, Inc. Therapeutics. Both companies will focus on the #US and #European markets. Amylin receptor activation has been shown to promote weight loss by restoring sensitivity to the satiety hormone leptin, which induces a feeling of fullness. In a Phase 1b multiple ascending dose trial, petrelintide resulted in a mean body weight reduction of 8.6% after 16 weeks, compared to 1.7% in the placebo group. Zealand Pharma will receive an upfront payment of US$1.65 billion, including US$1.4 billion at closing and US$250 million in anniversary payments over two years, with additional milestone payments totaling up to US$5.3 billion. The profits and losses from petrelintide and petrelintide/CT-388 will be shared equally between the two companies, while Zealand Pharma will also earn royalties on net sales in markets outside of the #US and #Europe. Zealand Pharma will pay Roche US$350 million for Carmot Therapeutics, Inc.’s GLP1/GIP receptor agonist CT-388, which will be part of the first combination product developed under this collaboration. The agreement grants Zealand Pharma the right to participate in up to 50% of #commercializationactivities in the #US and #Europe, with certain opt-in and opt-out provisions. Roche will have exclusive #commercialization rights for the #ROW (rest of the world) and will manage commercial #manufacturing and #supply. Roche has described Zealand Pharma’s amylin analog as having best-in-class potential, similar to the performance of CT-388, which demonstrated an 18.8% reduction in body weight after 24 weeks in a Phase IIb study. The deal is expected to close in the second quarter of 2025. Detailed news: https://lnkd.in/dD6ZbyCR Follow our page for more industry updates: https://lnkd.in/de5zNWmK Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv #Roche #ZealandPharma #ObesityTreatment #StrategicPartnership #WeightManagement #AmylinMimetic #Petrelintide #ObesityResearch #WeightLossSolution #RASLSSConsulting #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification

🌟 De Novo FDA Approvals in February 2025! 🌟 In February, the FDA approved two ground breaking #NewDrugs, representing significant advancements in the #Pharmaceutical industry. These #BreakthroughTherapies bring renewed hope and expanded treatment options for patients worldwide. It’s inspiring to see such advancements shaping the future of healthcare! SpringWorks Therapeutics Deciphera Pharmaceuticals ONO PHARMACEUTICAL CO., LTD. #USFDA #FDAApprovals #Pharmaceuticals #PharmaInnovation #BreakthroughTherapies #PatientCare #Gomekli #Romvimza #RASLSSConsulting #MarketIntelligence #MarketResearch #MarketEntryStrategy #CompetitiveIntelligence #StrategySupport #PortfolioOptimization Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv Follow our page for more industry updates: https://lnkd.in/de5zNWmK

Julphar has announced a significant milestone: an exclusive licensing partnership between Julphar with Dong-A ST!🚀 This collaboration will enable Julphar to ##tech transfer, manufacture, and commercialize Dong-A ST's #DarbepoetinAlfa biosimilar, a long-acting #Erythropoietin formulation developed by Dong-A ST, in the #MENA region. #DarbepoetinAlfa is a biotechnology product designed to address #anemia caused by #chronickidneydisease (CKD) in both dialysis and non-dialysis patients. The product offers patients a more efficient and longer-lasting treatment alternative compared to earlier formulations of erythropoietin. According to Basel Ziyadeh, CEO of Julphar, "This partnership aligns with Julphar's strategic vision to offer best-in-class products that meet the evolving needs of patients across the MENA region." Jung Jae-Hun, President of Dong-A ST, stated, "We will strive to expand access to Darbepoetin Alfa biosimilar for patients not only in the MENA region but also worldwide." This agreement reinforces Julphar's dedication to providing high-quality healthcare solutions and expanding its biologics portfolio. The partnership with Dong-A ST is anticipated to bring important new treatment options to patients in the region. Detailed News: https://lnkd.in/dWnthSFE Follow our page for more industry updates: https://lnkd.in/de5zNWmK Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv #Julphar #DongA #Biotechnology #MENA #Pharmaceuticals #StrategicPartnership #RASLSSConsulting #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification

Historic Advance in #StrokeTreatment: FDA Approves Genentech's #TNKase®   For the first time in nearly three decades, the FDA has approved a new stroke medication, Genentech's #TNKase® (tenecteplase), marking a pivotal moment in the fight against #acuteischemicstroke (AIS). #TNKase, a tissue plasminogen activator, is a clot-dissolving, thrombolytic medicine that works by breaking down fibrin, a key component of blood clots. TNKase offers a critical advantage: a single, 5-second IV bolus, dramatically faster than the standard 60-minute alteplase (Activase®) infusion. In stroke care, speed is paramount for improved patient outcomes. This approval is supported by the robust, multi-center AcT (Alteplase compared to Tenecteplase) trial, conducted by the University of Calgary, which demonstrated TNKase's comparable safety and efficacy to Activase. This reinforces Genentech's long-standing commitment to #strokecare, as they now provide both #TNKase and #Activase®, the only two FDA-approved medicines for AIS. Treatment should begin within three hours of symptom onset, and Genentech will introduce a new 25 mg vial to support this. With stroke a leading cause of disability, this advancement offers crucial hope for patients and their families.   Detailed News: https://lnkd.in/dkZd2F-V Follow our page for more industry updates: https://lnkd.in/de5zNWmK Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv #Stroke #AIS #FDAApproval #TNKase #Genentech #RASLSSConsulting #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification

Avecho Biotechnology Limited has entered into an exclusive ten-year development and licensing agreement with Sandoz Group AG ("Sandoz"), granting Sandoz the commercial rights to Avecho’s Phase III #cannabidiol ("CBD") capsule for #insomnia in #Australia. Avecho will retain the rights to commercialize the product in all other regions, while Sandoz holds the first right of refusal for these markets. The CBD capsule aims to become the first pharmaceutical CBD product registered as an over-the-counter medicine with the Therapeutic Goods Administration ("TGA"), with market projections estimating potential annual sales exceeding US$125 million in Australia. Under the agreement, Sandoz will pay an upfront licensing fee of US$3 million (approximately A$4.8 million) for exclusive #commercialization rights in #Australia. Avecho Biotechnology Limited will continue to finance and oversee the ongoing Phase III clinical trial, after which both companies will collaborate to obtain TGA regulatory approval. Sandoz will purchase the finished product from Avecho and take charge of its commercialization, including marketing and distribution in Australia. Additionally, Avecho is eligible for development milestone payments totaling US$16 million before commercialization and will receive tiered royalties of 14% to 19% on net sales once the product is launched. The agreement has an initial term of 10 years, with automatic extensions for two additional two-year renewal periods unless terminated by mutual consent. Detailed news: https://lnkd.in/dRhNt6Wm Follow our page for more industry updates: https://lnkd.in/de5zNWmK Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv ##Avecho #Sandoz #Cannabidiol #Insomnia #CBDforSleep #MedicalCannabis #OTCMedicine #TGAApproval #DrugDevelopment #RASLSSConsulting #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification

Celebrating a decade of impact, AstraZeneca's #HealthyHeartAfrica (HHA) initiative has marked its 10th anniversary, a testament to its unwavering commitment to improving #healthequity in #Africa. Over the past decade, HHA has made significant strides in combating non-communicable diseases (NCDs), particularly #hypertension. Key achievements include conducting more than 67 million blood pressure screenings, training over 11,700 healthcare professionals, and activating more than 1,550 healthcare facilities for hypertension management. With hypertension affecting over 27% of African adults, HHA's work is vital. The initiative is now expanding its focus to include chronic kidney disease (CKD), addressing the interconnected nature of NCDs. The success of HHA is built on strong partnerships with governments, NGOs like #PATH, and community leaders. The integration of NCD indicators into national health systems, as highlighted by PATH, is a significant milestone. As AstraZeneca approaches the WHO’s High-Level Meeting on NCDs, HHA's achievements underscore the importance of collaborative action in addressing these critical health challenges. Looking ahead, HHA is committed to expanding its geographical reach, integrating climate-resilient healthcare strategies, and prioritizing early detection to deliver vital care to vulnerable communities across Africa. Detailed News: https://lnkd.in/dYQGpMKM Follow our page for more industry updates: https://lnkd.in/de5zNWmK Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv #HealthyHeartAfrica #NCDs #GlobalHealth #AstraZeneca #Uganda #CKD #WHO #RASLSSConsulting #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification